Shire (LON:SHP)‘s stock had its “overweight” rating reiterated by investment analysts at JPMorgan Chase & Co. in a research note issued on Wednesday.
Other analysts have also recently issued reports about the company. Barclays reiterated an “equal weight” rating and issued a GBX 4,000 ($54.24) target price on shares of Shire in a report on Monday, October 30th. Shore Capital reiterated a “buy” rating on shares of Shire in a report on Wednesday, September 20th. Kepler Capital Markets reiterated a “buy” rating and issued a GBX 4,600 ($62.38) target price on shares of Shire in a report on Wednesday, November 1st. Berenberg Bank reduced their target price on Shire from GBX 6,000 ($81.37) to GBX 5,900 ($80.01) and set a “buy” rating on the stock in a report on Tuesday, October 24th. Finally, Liberum Capital reiterated a “buy” rating and issued a GBX 4,200 ($56.96) target price on shares of Shire in a report on Monday, November 20th. Five investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of GBX 5,182.35 ($70.28).
Shares of Shire (SHP) opened at GBX 3,708.50 ($50.29) on Wednesday. The firm has a market capitalization of $33,740.00 and a PE ratio of 2,830.92. Shire has a twelve month low of GBX 3,435.50 ($46.59) and a twelve month high of GBX 5,067 ($68.71).
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
What are top analysts saying about Shire? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Shire and related companies.